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The Akt family of serine/threonine protein kinases are key regulators of multiple aspects of cell behaviour, including prolife-
ration, survival, metabolism, and tumorigenesis. Growth-factor-activated Akt signalling promotes progression through normal,
unperturbed cell cycles by acting on diverse downstream factors involved in controlling the G1/S and G2/M transitions.
Remarkably, several recent studies have also implicated Akt in modulating DNA damage responses and genome stability. High
Akt activity can suppress ATR/Chk1 signalling and homologous recombination repair (HRR) via direct phosphorylation of Chk1
orTopBP1 or,indirectly, by inhibitingrecruitment of double-strandbreak (DSB)resection factors,such as RPA,Brca1, and Rad51,
to sites of damage. Loss of checkpoint and/or HRR proﬁciency is therefore a potential cause of genomic instability in tumor cells
with high Akt. Conversely, Akt is activated by DNA double-strand breaks (DSBs) in a DNA-PK- or ATM/ATR-dependent manner
and in some circumstances can contribute to radioresistance by stimulating DNA repair by nonhomologous end joining (NHEJ).
Akt therefore modiﬁes both the response to and repair of genotoxic damage in complex ways that are likely to have important
consequences for the therapy of tumors with deregulation of the PI3K-Akt-PTEN pathway.
1.Akt FamilyKinases
As one of the most versatile kinase families, Akt (also known
as PKB) serine-threonine kinases function as critical regula-
tors of cell survival, proliferation, metabolism, and migra-
tion. Deregulation of Akt kinases is frequently associated
with human diseases such as cancer and diabetes. Three iso-
forms of Akt have been identiﬁed in mammals: Akt1, Akt2,
and Akt3 [1–3]. The Akt isoforms share approximately 80%
amino acid identity and are thought to have similar primary
substrate speciﬁcity [4]. They are widely expressed in various
tissues; Akt1 is most abundant in brain, heart, and lung,
whereas Akt2 is predominantly expressed in skeletal mus-
cle and embryonic brown fat. Akt3 is mainly expressed in
kidney, brain, and embryonic heart [3, 5–7]. Findings from
Akt isoform-speciﬁc knockout mice suggest that Akt family
kinases are likely to have distinct biological functions in
vivo. Thus, Akt1 knockout mice are smaller than littermate
controls and show increased rates of apoptosis in some
tissues, reﬂecting the role of Akt1 in cell survival [8, 9]. By
contrast, Akt2 null mice develop type 2 diabetes and im-
paired glucose utilization, suggesting that Akt2 function is
more speciﬁc for the insulin receptor signaling pathway
[10, 11]. The precise role of Akt3 is less clear, however, mice
lacking Akt3 display impaired brain development [12].
All three Akt isoforms share a conserved N-terminal
pleckstrin homology (PH) domain, a central kinase domain,
and a C-terminal regulatory domain which contains the
hydrophobic motif, a characteristic of the cAMP-dependent
protein kinase A/protein kinase G/protein C (AGC) super-
family of protein kinases [13]. In response to various growth
factors and cytokines, Akt activity is modulated downstream
of phosphatidylinositol 3 (PI3) kinase via a multistep
process. Activated PI3 kinase localizes to the cytoplasmic2 Journal of Oncology
face of the plasma membrane, where it converts PIP2
(phosphatidylinositol 4,5-bisphosphate) to PIP3 (phosphati-
dylinositol 3,4,5-trisphosphate). PIP3 functions to acti-
vate downstream signaling components by recruiting pro-
teins containing PH domains to the plasma membrane, such
as Akt and PDK1 kinases [14–17]. Once recruited to the
plasma membrane, Akt is activated by site-speciﬁc phos-
phorylation at residues Thr308 and Ser473. PDK1 phospho-
rylates Thr308 within the activation T-loop of the cat-
alytic domain [18]. Ser473 within the carboxyl terminal
hydrophobic domain can be phosphorylated by mammalian
target of rapamycin complex 2 (mTORC2) [19]; however,
other molecules, including integrin-linked kinase (ILK) and
mitogen-activated protein kinase-activated protein linase-2
(MAPKAPK2),havealsobeenreportedtophosphorylatethis
residue [20, 21].
Once activated, Akt phosphorylates numerous substrates
throughout the cell to regulate multiple cellular events
and processes. Akt can also be activated in a PI3K-inde-
pendent manner. For example, cAMP elevating agents have
been shown to activate Akt through PKA [22, 23], whilst
Ca2+/calmodulin-dependent kinase can directly phosphory-
late and activate Akt in vitro [24, 25]. Several nonkinase
interactors such as Hsp90, Hsp27, Tcl1, Geb10, and Ft1
have also been described to positively regulate Akt catalytic
activity [13].
Negative regulation of PI3K/Akt pathways is mainly ac-
complished by PTEN (phosphatase and tensin homologue
deleted on chromosome 10). PTEN was originally identiﬁed
as a tumor-suppressor gene and is frequently mutated in a
wide variety of solid tumors, including endometrial, breast,
prostate carcinomas, and glioblastomas [26–28]. As a dual
lipid and protein phosphatase, the primary physiological tar-
get of PTEN is considered to be the PI3K/Akt pathway [29–
31]. PTEN speciﬁcally catalyses dephosphorylation of the 3
phosphate of the inositol ring in PIP3, resulting in the bip-
hosphate product PIP2 and inhibition of Akt activity [32].
Inactivating mutations or loss of PTEN expression leads to
a permanent increase in the basal level of PI3K/Akt signal-
ing, generally resulting in increased cell proliferation and
resistance to apoptosis.
Recently, a family of novel protein phosphatases, namely,
PHLPP (PH domain and leucine-rich repeat protein phos-
phatase), have been identiﬁed as important regulators of
Akt kinases and protein kinase C (PKC) [33–35]. Two iso-
forms, PHLPP1 and PHLPP2, directly dephosphorylate
Ser473 and therefore inactivate Akt. It has been shown that
PHLPP diﬀerentially terminates Akt signaling by regulating
distinct Akt isoforms. PHLPP2 dephosphorylates Akt1 and
Akt3, whereas PHLPP1 is speciﬁc for Akt2 and Akt3 [35].
Several lines of evidence suggest that PHLPP functions as a
tumor suppressor. PHLPP expression is commonly lost in
cancer, including colon, breast, ovarian, Wilms tumors, and
prostate cancer [33, 36, 37]. Overexpression of PHLPP1 in
a glioblastoma cell line inhibits tumor growth in xenografted
nudemice[34],anddecreasedexpressionofPHLPPhasbeen
linked to the metastatic potential of 21T breast cancer cells
[38]. Codeletion of PHLPP1 and PTEN is strongly associated
with metastatic prostate cancer and tightly correlated to
deletion of p53 and PHLPP1, suggesting the role of PHLPP
as a prostate tumor suppressor [37].
2. Role of Akt in Normal Cell Cycle Progression
Remarkable progress has been made in determining how
Akt promotes cell cycle progression. Activated Akt kinase
modulatesthefunctionofnumeroussubstratesrelatedtocell
cycle progression at the G1/S and G2/M transitions, either by
direct phosphorylation of the target proteins themselves or,
indirectly, by regulating protein expression levels. These are
discussed in detail in the following and depicted in Figure 1.
2.1. Mechanisms of Akt Regulation of G1/S Progression. Addi-
tion of mitogens to quiescent (G0) mammalian cells rapidly
triggers a number of biochemical signalling cascades, includ-
ing the PI3K/Akt pathway, to promote cell growth through
two key enzymes mTOR and p70S6K [39–42]. As depicted
in Figure 1, growth-factor-mediated Akt activation increases
the transcription of c-Myc, a strong promoter of cell cycle
progression, causing cells to exit G0 both by inducing the
expression of D-type cyclins and suppressing the expression
o fm u l t i p l en e g a t i v ec e l lc y c l er e g u l a t o r ss u c ha sp 2 1 Cip1,
p27Kip1, and p15INK4b [43, 44]. Akt also controls the stability
of c-Myc and cyclin D1 indirectly via its downstream sub-
strate, GSK-3β.G S K - 3 β phosphorylates c-Myc at Thr58,
which appears to be required for ubiquitin-dependent
proteolysis [45, 46]. Cyclin D1 is phosphorylated by GSK-3β
at Thr286, a modiﬁcation that induces nuclear-cytoplasmic
translocation of cyclin D1 leading to ubiquitin-dependent
proteolysisinthecytoplasm[47,48].Furthermore,PI3K/Akt
is also necessary and suﬃcient to induce E2F transcriptional
activity in T cells through phosphorylating and deactivating
Rb [49].
Another important function of Akt in G1/S progres-
sion is positive regulation of mid- and late-G1-phase cyc-
lin/Cdk activity viaphosphorylation and inactivation of Cdk
inhibitors,includingp21Cip1 andp27Kip1.Aktphosphorylates
p21Cip1 at Thr145, within its nuclear localization sequence
(NLS), to recruit p21Cip1 from the nucleus to the cytoplasm
and suppress its inhibitory eﬀect on cell cycle progression
[50]. Akt-mediated T145 phosphorylation also prevents
p21Cip1 forming a complex with PCNA to inhibit DNA repli-
cation and decreases its binding to Cdk2/Cdk4 and attenu-
ates its Cdk2 inhibitory activity [51]. In addition to Thr145,
Ser146 is also phosphorylated by Akt, a modiﬁcation that
signiﬁcantly increases p21Cip1 protein stability and protects
cellsfromtaxol-inducedapoptosis [52]. Importantly, p21Cip1
protein induced by Akt does not inhibit cyclin E-Cdk2 but
rather promotes the assembly and activation of cyclin D1-
Cdk4 complex, which controls G1 to S phase progression
and enhances cell cycling [52]. p21Cip1 e l e v a t i o ni nt u m o r s
correlates with enhanced survival and chemoresistance [53],
indicating that stabilization of p21Cip1 by Akt would be
beneﬁcial for tumor growth.
As with p21Cip1, the expression, localization, and pro-
tein stability of p27Kip1, are controlled by Akt-dependent
phosphorylation. Akt is known to downregulate p27Kip1Journal of Oncology 3
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Figure 1: Role of Akt in normal cell cycle progression. Activated Akt kinase modulates the function of numerous proteins involved in cell
cycle progression at the G1/S and G2/M transitions, either by direct phosphorylation of the target proteins themselves, or indirectly, by
regulating protein expression levels. Please see text for additional explanation.
transcription by phosphorylation-dependent inhibition of
theForkheadfamilyoftranscriptionfactors[54].Aktdirectly
binds to and phosphorylates p27Kip1 at three residues, Ser10,
Thr187, and Thr198 [55–58]. Ser10 phosphorylation could
increase the nuclear export of p27Kip1 through binding to
CRM1, but it is not suﬃcient to promote the cytoplasmic
localization of p27Kip1 because an S10D mutant remains in
the nucleus in G0/G1 cells [59]. Thr157 is within the nuclear
localization sequence (NLS), and phosphorylation by Akt
favours cytoplasmic accumulation of p27Kip1 [55–57, 60].
When forced to localize to the cytoplasm, p27Kip1 is less
eﬃcient in binding and inhibiting nuclear cyclin E-Cdk2
kinase activity and thus halting cell cycle progression [55–
57]. Phosphorylation of C-terminal Thr198 by Akt promotes
14-3-3 binding and cytoplasmic localization of p27Kip1 [58].
Remarkably, cytoplasmic mislocalization of p27Kip1 has been
observed in various human tumors [61, 62]. In up to 40%
of primary human breast cancers, cytoplasmic p27Kip1 corre-
lates with Akt activation, indicating that Akt-mediated cyto-
plasmic mislocalization of p27Kip1 m a yb ec r i t i c a li nt h ed e -
velopment of human cancers [55].
Interestingly, recent studies revealed that the protein
stability of p27Kip1 is controlled by Akt-dependent phospho-
rylation of Skp2 [63, 64]. Skp2 is a key component of SCF
(Skp1/Cul-1/F-box) E3 ubiquitin ligase; it binds to p27Kip1
and targets it for ubiquitination and degradation [65–68].
Akt interacts with and directly phosphorylates Skp2 at Ser72,
which triggers SCF complex formation and E3 ligase activity
[63]. In addition, phosphorylation by Akt promotes the
cytoplasmic localization of Skp2 and protects Skp2 from
APC-Cdh1-mediated degradation [64]. High levels of active
Akt correlates with the cytosolic accumulation of Skp2 in
aggressive breast and prostate cancer patients, providing
a rationale to develop speciﬁc Akt inhibitors as eﬃcient
anticancer drugs [64].
At the end of G1 phase, a series of safeguards ensure that
theDNAisintactandthecellisreadytoinitiateDNAreplica-
tion. DNA damage and other stresses can activate the tumor
suppressor p53, which binds to DNA and up-regulates the
expression of several genes involved in cell cycle control,
DNA repair, senescence, angiogenesis, and apoptosis [69,
70]. In normal cells p53 is maintained at very low levels,
and Mdm2 targets p53 for ubiquitination and allows export
of p53 from the nucleus to the cytoplasm where proteolysis
takesplace[71,72].Inresponsetogrowthfactorstimulation,
active Akt binds to and phosphorylates Mdm2 at Ser166 and
Ser186 to enhance protein stability and facilitate the func-
tion of Mdm2 to promote p53 ubiquitination [73, 74]. Akt
phosphorylation of Mdm2 is also necessary for the trans-
location of Mdm2 from the cytoplasm to the nucleus. Domi-
nant-negative Akt inhibits nuclear entry of Mdm2, thus in-
creasing the cellular level of p53 and transcriptional activity
[75]. A close homologue of Mdm2, MdmX, has also been
shown to be an Akt target. Unlike Mdm2, MdmX does not
possess E3 ubiquitin ligase activity; however, it binds to and
stabilizes Mdm2. The heterocomplex of Mdm2-MdmX is
more eﬃcient for p53 ubiquitination [76, 77]. Akt also phos-
phorylates MdmX at Ser367, which generates a 14-3-3 bind-
ing site and leads to the stabilization of the Mdm2-MdmX
complex [78]. Thus, oncogenic Akt is able to function-
ally inactivate p53 by regulating Mdm2 and MdmX stability.
2.2. Mechanisms of Akt Regulation of G2/M Progression.
It has been reported previously that Akt activity is high
in the G2/M phase of the cell cycle in epithelial cells4 Journal of Oncology
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Figure 2: Crosstalk between Akt and DNA damage signalling pathways. Akt can be activated in response to DNA damage through the action
of the PI3 kinase-like kinases (PIKKs) ATM, ATR, and DNA-PK. Conversely, active Akt can promote DNA repair via NHEJ and inhibit
checkpoint signalling and repair via recombination through multiple mechanisms and targets. Please see text for additional explanation.
[79]. Akt activity protects cells from apoptosis during the
G2/M transition and is necessary for eﬃcient entry to
mitosis during unperturbed cell cycles [79, 80]. As shown in
Figure 1, Akt regulates the G2/M transition through direct
phosphorylation of both Cdk1 activators and inhibitors,
suggesting that the PI3K/AKT pathway could function to
promote mitosis [81, 82].
As one of the three human members of Cdc25 family
of dual-speciﬁcity phosphatases, Cdc25B plays an important
role in the control of the activity of Cdk1/cyclin B [83]. The
function of Cdc25B is tightly linked to its intracellular locali-
zation [84]. During the G2/M transition, Cdc25B shuttles
between the nucleus and the cytoplasm as a result of the op-
posing actions of the nuclear localization (NLS) and nuclear
export signals (NES) in association with 14-3-3 family mem-
bers [81]. Akt-mediated Ser353 phosphorylation regulates
the cytoplasmic accumulation of Cdc25B and contributes to
mitotic entry by promoting its inactivation and access to
speciﬁc substrates [82]. The Cdk1 inhibitor Wee1Hu (also
known as Wee1A) is an Akt substrate in mammalian cells
[85]. Akt binds to and phosphorylates Wee1Hu at Ser642
within its C-terminal catalytic domain during late S and
G2 phase. Ser642 phosphorylation does not aﬀect the kin-
ase activity; however, it promotes cytoplasmic localization
of Wee1Hu through binding to 14-3-3θ [85]. As a result,
coexpression of Akt together with Wee1Hu and 14-3-3θ
overcomes the G2/M arrest induced by Wee1Hu alone [85].
Another Cdk1 inhibitor Myt1 has also been shown to be a
substrate for Akt in oocytes from the starﬁsh Asterina pec-
tinifera [86]. Akt phosphorylates Myt1 at Ser75 and severely
reduces Myt1-mediated Tyr15 Cdk1 phosphorylation result-
ingintheactivationofcyclinB-associatedCdk1kinaseactiv-
ity [86]. Microinjection of nonphosphorylated mutant Myt1
completely abolishes 1-MdAde-induced meiotic reinitia-
tion [86]. Thus, the direct phosphorylation of Myt1 by Akt
reverses the balance between Myt1 and Cdc25 activities and
initiates the activation of cyclin B-Cdc2 to cause meiotic
G2/M-phase transition.
ArecentstudysuggeststhatAktcanalsoregulatethepro-
gressionofStoG2phaseviaphosphorylationofCdk2.There
is a transient nucleocytoplasmic shuttling of Akt during late
Sa n dG 2p h a s e s[ 87]. Nuclear Akt phosphorylates Cdk2 at
Thr39 which causes temporary cytoplasmic localization of
cyclin A/Cdk2 complex. The cytoplasmic redistribution of
Cdk2 is required for cell cycle progression from S to G2/M
phase, as nonphosphorylated Cdk2 T39A mutant severely
aﬀects cell cycle progression. In addition to its role in cell
cycle progression, Akt-mediated phosphorylation and cyto-
plasmictranslocationofCdk2isalsoimportantforapoptosis
induced by stresses such as methotrexate and docetaxel [87].
Phosphorylated Cdk2 is sequestered in the cytoplasm and
directed to diﬀerent cytoplasmic substrates including p53,
ultimately leading to cell death [87, 88].
3. Role of Akt in Genome Stability
3.1. Akt Regulation in Response to DNA Damage. As depicted
in Figure 2, Akt is activated not only by growth factors but
also by DNA damage [18, 89]. The PIKK family members
ATM, ATR, and DNA-PK are involved in Akt activation inJournal of Oncology 5
response to genotoxic stresses, which may provide a prosur-
vival signal by triggering cell cycle arrest or inhibiting apop-
tosis [90–93].
In vertebrates, ATM is recruited to and activated pri-
marily at DNA double-strand breaks in conjunction with
MRN(Mre11:Rad50:NBS1)complex.Onceactivated,ATM
triggers the phosphorylation of multiple substrates at the site
of damage, such as H2AX, Chk2, and tumor suppressor p53,
leading to cell cycle arrest, DNA repair, or apoptosis. Muta-
tion of the ATM-gene results in Ataxia telangiectasia (AT),
a rare human disease characterized by growth retardation,
severe immunodeﬁciency, insulin resistance, hypersensitivity
to radiation, and predisposition to cancer [94]. Interestingly,
Akt knockout mice show some similar phenotypic abnor-
malities to ATM-deﬁcient mice, such as growth retardation,
insulin resistance, hypersensitivity to gamma-irradiation,
and immunodeﬁciency [8, 11, 95], indicating that ATM and
Akt may be involved in the same signalling transduction
pathway. Viniegra et al. provide clear evidence that ATM acts
as an upstream activator of Akt in response to insulin or γ-
radiation [91]. Overexpression of exogenous ATM and Akt
in Cos cells promotes Akt Ser473 phosphorylation by in-
sulin or IR and the phosphorylation depends on the PI3K-
like catalytic domain of ATM. Although ATM binds to Akt
directly, there is no apparent direct phosphorylation of Akt
Ser473 by ATM, suggesting that other intermediate protei-
ns downstream of ATM may be involved in direct phospho-
rylation of Akt in response to insulin or IR. Interestingly,
another study by Caporali et al. demonstrates that ATR, but
not ATM, is required for Akt phosphorylation at Ser473 in
responsetotemozolomide(TMZ),atherapeuticmethylating
agent [93]. siRNA-mediated knockdown of ATR but not
ATMexpressionresultsinabrogationofTMZ-inducedphos-
phorylation of Akt [93]. However, there is no clear evidence
that ATR phosphorylates Akt directly in response to TMZ. It
is possible that ATR mediates activation of another kinase to
phosphorylate Akt.
It has been proposed that DNA-PK (DNA-dependent
protein kinase) is also involved in Akt activation in response
to DNA damage such as IR and doxorubicin [92]. This path-
wayisspeciﬁcforDNAdamageasDNA-PKisdispensablefor
Akt Ser473 phosphorylation upon insulin or growth-factor
stimulation [92]. Interestingly, phosphorylated Akt forms
nuclear foci and colocalizes with DNA-PK at double-strand
DNAbreaksandtheinteractionbetweenAktandDNA-PKis
DNA damagedependent [92]. Akt1 knockout mice resemble
the DNA-PK deﬁciency radiosensitivity phenotype, with
attenuated p21Cip1 expression and increased apoptosis in res-
ponse to DNA damage, supporting the notion that DNA-
PK/Akt1 pathway has a marked impact on cell survival after
DNA damage due to transcriptional regulation of p21Cip1
[92]. Beside Akt1, Akt2 and DNA-PK are also required for
the stabilization of p53 in response to IR, which is mediated
by the inactivation of GSK-3 [96]. The above results suggest
a novel mechanism through which DNA-PK phosphorylates
and activates Akt at the site of DNA double-strand breaks.
This process triggers the induction of a transcriptional pro-
g r a mt h a tp r o m o t e sc e l ls u r v i v a li nr e s p o n s et oD N Ad a m a -
ge. Whether DNA-PK directly phosphorylates Akt itself or
acts through PDK1 and whether DNA-PK and Akt interact
directly remain unclear [97, 98].
3.2. Akt Modulates DNA Damage Checkpoint Signalling and
DNA Repair. Mounting evidence implicates the role of Akt
inmodulatingcheckpointresponsesandDNArepair.Activa-
tion of Akt overcomes DNA-damage-induced G2 arrest and
apoptosis in a p53-independent manner [80, 99–102]. Over-
expression of a constitutive active form of Akt or loss of
PTEN abrogates G2 cell cycle checkpoint and Chk1 activa-
tion upon exposure to genotoxic stresses [80]. In addition,
Akt-mediated suppression of G2 arrest is associated with
reduced recruitment of Chk2 to sites of DNA damage and
inhibition of Chk2 activation in human glioblastoma cells
[103].TheabilityofAkttosuppressG2arrestinducedbydis-
parate agents suggests that Akt has a broad ability to override
this checkpoint regardless of the pathway by which the pro-
cess is initiated [103].
As the most hazardous DNA lesions, DNA double-strand
breaks (DSBs) can lead to genome rearrangements and cell
death following exposure to genotoxic stresses. Two mecha-
nisms are primarily involved in repair of DSBs: nonhomo-
logous end joining (NHEJ) and homologous recombination
repair(HRR)[104,105].NHEJisevolutionarilyconservedin
all kingdoms of life and is the predominant DSB repair path-
way throughout the cell cycle [106–108]. HRR is a more ac-
curate repair mechanism but restricted to S and G2 phases
[109, 110]. Numerous studies have shown that inhibition
of Akt activity impairs DSB repair [111–115]. Speciﬁc
Akt inhibitors or AKT1 siRNA markedly reduce radiation-
invduced DNA-PKcs phosphorylation at T2609 and S2056,
modiﬁcations required for activation of DNA-PKcs [116,
117]. Akt1 physically associates with DNA-PKcs, indicating
that Akt1 may function as a signalling kinase relevant for
DNA-PKcs activation and NHEJ repair [111–115]. It has
been shown in malignant glioblastoma that EGFR/ERK/Akt
signalling promotes γH2AX foci resolution and enhances
both NHEJ and HR repair by modulating the localization,
expression, and phosphorylation of DNA-PKcs, ATM, and
Rad51.InhibitionofeitherAktorMEK/ERKresultsinsignif-
icant reduction of NHEJ [115]. These results strongly argue
that both Akt and MEK/ERK signalling are critical eﬀectors
downstream of EGFR that modulate DNA repair and may
contribute to radioresistance in malignant glioblastoma with
deregulated EGFR/ERK/Akt signalling. Interestingly, recent
studies show that DNA-PKcs acts as an upstream signal for
Akt phosphorylation and activation in response to genotoxic
stresses [92, 96, 118], suggesting that Akt and DNA-PKcs are
tightly coregulated in both checkpoint response and DNA
repair.
The activation of HRR in S and G2 phases regulates the
accurate repair of DNA lesions, but unregulated HRR could
result in ampliﬁcation of repeated genomic sequences and
loss of heterozygosity [119, 120]. In contrast to the positive
role of Akt in modulating NHEJ repair, however, recent
studies reveal that oncogenic Akt promotes genome insta-
bility by repressing HRR under pathologic circumstances.
In breast cancer cell lines with high level of Akt1 activity,6 Journal of Oncology
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additional explanation.
IR-induced Brca1 and Rad51 foci formation and HRR are
strongly impaired compared to cells with low Akt1 activity
[121].Biopsiesofsporadicbreastcancerpatientsshowstrong
correlation of Akt1 activation with cytoplasmic Brca1 and
Rad51 localization [121]. In addition, active Akt1 induces
supernumerary centrosomes and aneuploidy in hamster
ovary cells [121].
The above results indicate a novel oncogenic function for
Akt1 by producing genomic instability as a consequence of
HRR repression, which may play an important function in
the pathology of sporadic breast and ovarian cancer [121].
Recent studies by us also provide additional evidence and in-
sight into mechanisms of genomic instability resulting from
high level of active Akt due to loss of PTEN. In HCT116 cells
ectopically expressing constitutively active Akt or lacking
PTEN, both DNA-damage-induced RPA, CtIP and Rad51
foci formation and Chk1 activation are markedly suppress-
ed. Conversely, inhibition of Akt by either selective chemical
inhibitors or Akt siRNA restores DNA-damage-induced
recruitment of RPA, CtIP, and Rad51 and Chk1 activation.
Thus, the inhibitory eﬀect of Akt on ATR-Chk1 signalling
and HRR could be due to suppression of DNA damage pro-
cessing [122].
3.3. Akt Targets Involved in DNA Damage Responses. Akt
is thought to phosphorylate up to 100 substrates, some of
which have been implicated in DNA damage checkpoint
response and DNA repair. For instance, direct phosphoryla-
tionofcellcyclecheckpointkinaseChk1,TopBP1,Brca1,and
RPS3 by Akt is important for the activation of DNA damage
signallingcascade[101,123–125](Figure 3).Inaddition,Akt
activity is pivotal for the focal accumulation of key factors
regulating DSB resection and DNA repair, including Rad51,
Brca1, CtIP, and RPA [100, 121, 122, 126].
3.3.1. Chk1. As a key checkpoint kinase, Chk1 is activated by
a wide range of genotoxic stresses. Activated Chk1 is essen-
tial for G2/M and replication checkpoint proﬁciency when
DNA is damaged or replication is incomplete [127–130].
Chk1isdirectlyphosphorylatedbyAktatSer280,amodiﬁca-
tion that results in cytoplasmic sequestration [79, 99, 101,
123]. Ser280 phosphorylated Chk1 covalently associates with
ubiquitin, ubiquitination of Chk1 does not alter the protein
stability; however, it promotes enhanced cytoplasmic locali-
zation and inhibition of checkpoint function [101, 123]. The
increased cytoplasmic distribution of Chk1 is also seen in
primary breast carcinomas tissues with elevated Akt phos-
phorylation and reduced PTEN level [101, 123]. Beside
regulating the subcellular localization, Akt phosphorylation
alsoinhibits thephysicalinteractionbetweenChk1andClas-
pin, which results in the inhibition of Chk1 activity and
checkpoint proﬁciency [124]. By contrast, a recent study by
Tonicetal.questionsthesigniﬁcanceofChk1S280phospho-
rylation on the checkpoint function, since overexpression of
exogenous Chk1 S280E mutant does not override radiation-
induced G2 arrest [100]. This apparent discrepancy may be
attributable to variable basal levels of active Akt in diﬀerent
cell lines.Journal of Oncology 7
3.3.2. TopBP1. DNA topoisomerase 2-binding protein 1
(TopBP1) is an evolutionally conserved BRCT domain-rich
protein that plays a critical role in DNA replication, DNA da-
mage checkpoint responses, and transcriptional regulation
[131]. In response to genotoxic stresses, TopBP1 colocalizes
and interacts with ATR/ATRIP and promotes phosphoryla-
tion of Rad9 in the 9-1-1 (Rad9-Rad1-Hus1) clamp. The C-
terminal ATR-activating domain of TopBP1 then stimulates
the kinase activity of ATR [132, 133]. Akt phosphorylates
TopBP1 at Ser1159, a consensus sequence conserved in hu-
man, mouse, rat, and Xenopus. This modiﬁcation induces
oligomerization of TopBP1 through its seventh and eighth
BRCT domains, and this self-association is crucial for its in-
teraction with E2F1 and transcriptional repression [134].
Ser1159 phosphorylation may also prevent association of
ATR with TopBP1 after DNA damage, thus inhibiting activa-
tion of ATR and G2/M checkpoint proﬁciency [124].
3.3.3. Brca1. The tumor suppressor and breast cancer susce-
ptibility gene 1 (Brca1) has been shown to play an integral
role in regulating DNA repair, cell cycle checkpoints, tran-
scription, and maintenance of genomic stability. As one of
the key players regulating DSB repair, Brca1 forms nuclear
foci in response to DNA damage where it colocalizes with
Rad51 and facilitates Rad51 ﬁlament formation to initiate
HR repair. It has been reported recently that oncogenic Akt1
can repress HRR by inducing cytoplasmic retention of Brca1
in human cancer cells [100, 121]. Importantly, cytoplasmic
retention of Brca1 is strongly correlated with activated
Akt1 in biopsies from sporadic breast cancer patients [121].
Although Akt is able to phosphorylate Thr509 of Brca1
within the nuclear localization sequences (NLS), there is no
direct evidence that Thr509 phosphorylation is required for
cytoplasmic localization of Brca1 [135–137]. One potential
scenario could be that Thr509 phosphorylation prevents
Brca1 interacting with other proteins that localize to DNA
damage foci. Conversely, Brca1 could also regulate Akt path-
way in a negative manner. Brca1 interacts with phospho-Akt
through Brca1-BRCT domains leading to its ubiquitination
and degradation, thereby downregulating Akt signalling
[138].Thus,elucidationoftheprecisemolecularfunctionsof
Brca1-Akt pathway will be particularly important to under-
standtumorigenesisofhereditaryandsporadicbreastcancer.
3.3.4. RPS3. Ribosomal protein S3 (RPS3) is a component
of the 40S ribosomal subunit which is required for ribosome
biogenesis[139].Apartfromitsribosomalfunctions,RPS3is
also known as UV endonuclease III which participates in the
cleavageofDNAlesionsinducedbyUVirradiation.RPS3has
apurinic/apyrimidinic (AP)2 endonucleaseactivityfunction-
ing in DNA repair at the 3 of the AP sites after DNA damage
[140–142]. A recent study by Lee et al. demonstrates that
RPS3 is a physiological target of Akt and a novel mediator of
neuronal apoptosis. Akt physically binds to and phosphoryl-
ates RPS3 at Thr70. Akt-dependent phosphorylation sup-
presses the proapoptotic function of RPS3 by governing its
nuclear accumulation and enhancing its endonuclease acti-
vity [125]. It is conceivable that Akt promotes cell survival
after DNA damage by regulating the DNA repair activity of
RPS3 [143, 144]. Manipulation of nuclear RPS3 and its Akt-
mediated phosphorylation might provide a new dimension
for therapeutics of neurological diseases.
Several lines of evidence demonstrate the role of Akt in
manipulating the subcellular localization or expression of
the key factors regulating checkpoint response and DNA re-
pair.OverexpressionofconstitutiveactiveformofAktorloss
of PTEN disrupts the nuclear foci formation of DNA-PKcs,
Rad51, Brca1, CtIP and RPA in response to DNA damage
[121, 126]. The cytoplasmic retention of Brca1 and Rad51
also correlates with activated Akt1 in sporadic breast can-
cer tissues [121, 126]. In addition, it has been proposed that
Akt activity could regulate the expression of Mre11 through
GSK3β/β-catenin/LEF-1 pathway, which promotes the repair
of radiation-induced DSBs in both CNE2 and HeLa cells
[145]. The PI3K/Akt signalling pathway also acts together
with MKK1/2-ERK1/2 to control Rad51 expression and pro-
tein stability in human non-small-cell lung cancer cells
(NSCLCs) [146, 147].
4. Implications for Cancer
Development andTherapy
Akt signaling is frequently activated in human cancers due to
genetic and epigenetic alterations and has a role in neoplastic
transformation [148–152]. Although Akt gene mutations are
not widely reported, the ampliﬁcation, overexpression, and
activation of Akt occurs at high frequency in a number of
human cancers [148, 150]. Alterations of Akt signalling in
human cancer also result from mutations of the upstream
PI3K kinase and PTEN. PTEN is one of the most frequently
m u t a t e dg e n e s ,s e c o n do n l yt op 5 3i nh u m a nc a n c e r s
[30, 153]. Inactivation of PTEN is strongly correlated with
the activation of Akt which in turn controls tumor cell
proliferation. PTEN activity is lost by mutation, deletion, or
promoter methylation silencing at high frequency in many
primary and metastatic human cancers [154–156]. Many
activating mutations have also been described in PI3KCA
gene, upstream of Akt, which encodes one of the p110α cata-
lytic subunits of PI3K. PI3KCA mutations (E542K, E545K,
H1047R) are frequently observed in human colon, gastric,
breast, and lung cancers and glioblastoma. They are able to
constitutively activate Akt and enhance its oncogenic activity
[157–162].
The early stages of neoplasia are often associated with
spontaneous genotoxic stresses resulting in DNA damage. If
the damage is not repaired, DNA injury can result in muta-
tion of tumor suppressor genes and activation of oncogenes,
triggering uncontrolled cell proliferation and genome insta-
bility, the major cause of cancer. Inherited mutations that
aﬀect DNA repair genes are associated with human cancers
[105, 163–166]. However, the majority of cancers are spo-
radic; thus, understanding the mechanisms of tumorigenesis
will be particularly important for cancer therapy. Recently,
mountingevidenceindicatethatAktsignallingpathwayplays
a key role in modulating DNA damage response and genome
stability in complex ways.8 Journal of Oncology
Table 1: Akt inhibitors currently in clinical trials.
Compound Description Phase Tumor
MK-2206 Allosteric kinase
inhibitor
I
Metastatic solid tumors, non-small-cell lung cancer, advanced solid tumors, breast
cancer, leukemia, lymphoma, neoplasms malignant, kidney cancer, prostate cancer,
brain and central nervous system tumors, small intestine cancer
II
Ovarian cancer, fallopian tube and primary peritoneal cancer, leukemia,
lymphoma, colorectal neoplasms, breast cancer, esophageal cancer, gastric cancer,
endometrial cancer, prostate cancer, recurrent nasopharyngeal carcinoma, head and
neck cancer, kidney cancer, lung cancer, extrahepatic bile duct cancer, gallbladder
cancer, liver cancer
Perifosine Lipid-based allosteric
kinase inhibitor
I
Pediatric solid tumors, multiple myeloma, solid tumors, colon cancer, renal cancer,
ovarian cancer, neoplasms, brain and central nervous system tumors, leukemia,
lymphoma
II
Malignant gliomas, CNS, brain cancer, Waldenstrom’s macroglobulinemia,
lymphomas, colon cancer, gastrointestinal stromal tumors, multiple myeloma,
chondrosarcomas, alveolar soft part sarcomas, kidney cancer, renal cell carcinoma,
leukemia, lymphoma, brain and central nervous system tumors, melanoma (skin),
endometrial cancer, sarcoma, prostate cancer, head and neck cancer, pancreatic
cancer, breast cancer
III Multiple myeloma, colorectal cancer
GSK-2141795 ATP competitive
inhibitor I Ovarian cancer, solid tumors, and lymphoma
GSK-2110183
ATP competitive
inhibitor I Multiple myeloma, hematologic malignancies
II Langerhans cell histiocytosis, hematologic malignancies
RX-0201 interfering RNA II Metastatic pancreatic cancer
Activated Akt may contribute to resistance to chemo-
or radiotherapy by stimulating NHEJ repair and promoting
cancer cell survival. Several considerations argue that this
may be the case. Firstly, the bulk of DSBs are repaired by
NHEJ which is active throughout the cell cycle and DNA-
PK is required for NHEJ repair. It has been shown that
Akt physically associates with DNA-PKcs and activates it by
phosphorylation [113]. In addition, DNA-PKcs could acti-
vate Akt in response to genotoxic stresses [92]. Therefore this
positivefeedbackloopcouldcontributetohighlyDNArepair
proﬁciency and chemo- or radioresistance in some tumor
cells with constitutive Akt activation. Secondly, oncogenic
Akt may contribute to genomic instability via abrogation of
cell cycle checkpoints, suppression of Chk1 activation and
HRR, as well as induction of supernumerary centrosomes
and aneuploidy. Taken together, activation of Akt pathway
potentially contributes to tumorigenesis and tumor cell
survivalthroughmultiplemechanisms.Futureworkwillseek
to evaluate the precise role of Akt in regulating these pro-
cesses.
Overthepastdecadenumerousstudieshaveaccumulated
supporting the idea that inhibition of PI3K/Akt pathway
leads to radiosensitization in glioblastoma and various carci-
nomas, including colon, bladder, prostate, head and neck,
and cervix [167–175]. The combination of PI3K inhibitor
and radiation causes an increase in apoptosis and a decrease
in clonogenic survival, whereas expression of constitutively
active Akt blocks apoptosis induced by radiation and pre-
vents radiosensitization by PI3K inhibitor, indicating that
activated Akt promotes cell survival through inhibition of
IR-induced apoptosis [167–175]. Akt activity also promotes
resistance tochemotherapy in breastcancerand ovarian can-
cercelllines[176,177].Whencombinedwiththerapiescom-
monly used in breast cancer treatment, the PI3K inhibitor
enhances apoptosis caused by doxorubicin, trastuzumab,
paclitaxel, etoposide, or tamoxifen, suggesting that inhibi-
tion of Akt in breast cancer patients may increase the eﬃcacy
of these therapies [176, 177]. Loss of PTEN and the presence
of active Akt are correlated with poor diﬀerentiation, lymph
node involvement, distant metastasis, and late stage in
NSCLC patients. Preclinical data suggest that modulation of
Akt activity sensitizes cells to chemo- or radiotherapy [89,
178] .T h ec o m b i n a t i o n so fd r u g st h a tm o d u l a t eA k ta c t i v a -
tion with the therapeutic modalities used in NSCLC are
thought to improve cancer treatment [150].
The PI3K/Akt/PTEN pathway therefore emerges as one
of most promising targets of anticancer drugs in the imme-
diate future. Currently, clinical trials with inhibitors of Akt
in monotherapy or combination with other anticancer drugs
are underway in cancer patients [150, 179]( Table 1). There
are several promising candidate Akt inhibitors, such as lipid-
based inhibitors that bind to the PH domain, ATP-com-
petitive and noncompetitive small molecule inhibitors, and
peptide-based inhibitors [150, 180, 181]. Perifosine (Keryx
Biopharmaceuticals, New York, NY, US) is a lipid-based
inhibitor which can inhibit the translocation of all Akt iso-
forms to the membrane by interacting with the PH domain
[182, 183]. In both preclinical and early clinical trials, perifo-
sine displays antiproliferative eﬀects in many tumor cell lines
and sensitizes tumor cells to radiation and chemotherapy in
vitro [183, 184]. Phase II clinical trials with perifosine com-
bined with radiotherapy, chemotherapy or other anticancerJournal of Oncology 9
agents are ongoing [150, 180]. MK-2206 (Merck and Co.,
Whitehouse Station, NJ, US) is an allosteric Akt inhibitor,
which induces a conformational change in the Akt protein
to inhibit both the activity and activation of the kinase
and blocks signal transduction through the PTEN pathway
[185, 186]. Preclinical studies demonstrate that MK-2206
exerts more potent tumor inhibitory activities when in com-
bination with other targeted therapies (erlotinib, lapatinib)
or cytotoxic agents such as doxorubicin, docetaxel, and 5-
ﬂuorouracil [187]. An oral phase I trial with MK-2206 in
patients with advanced solid tumors was just completed
[179, 188]. Currently, over 10 enrolling phase II clinical trials
with MK-2206 or combined with chemotherapy or targeted
anticancer therapy are ongoing in multiple tumor types
(http://clinicaltrials.gov/ct2/results?term=MK-2206). Other
orally dosed ATP competitive Akt inhibitors undergoing
phase I trials include GSK2141795 (GlaxoSmithKline, Brent-
ford,UK)andGSK2110183[189].ApotentATP-competitive
inhibitor GSK69069 shows strong eﬃcacy in xenograft
models from ovarian, prostate, and breast carcinoma cell
lines [150]. It is currently in clinical development as an
intravenous agent used in patients with solid tumors or
haematological malignancies [189]. The search for small
molecule inhibitor and peptide-based inhibitors is a new
frontier in drug discovery. Akt antisense inhibitors are also
being developed. RX-0201 represents an antisense oligonu-
cleotide to Akt1. A phase II ongoing clinical trial is assessing
the combination eﬃcacy of RX-0201 and gemcitabine in
metastatic pancreatic cancer [179, 190].
Beside that, inhibitors targeted upstream or downstream
of Akt such as PI3K and mTOR are more advanced in
their development than Akt inhibitors. Several PI3K and
mTOR inhibitors are in preclinical and phase II clinical
trials at present [189, 191]. Regarding the complexity
of PI3K/Akt/PTEN/mTOR signalling in diﬀerent types of
tumors, combinations of targeted therapeutics might be
required for eﬃcacy and safety for cancer treatment in the
future.
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